secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2026-05-13T20:11:27+00:00
Accession:  0001493152-26-022727
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q1 2026 revenue up 182% to $1.11M; net loss narrows to $(0.05)/share
---------------------------------------------------------------------------

- Q1 revenue $1,110,956 vs $393,572 YoY; net loss $(0.05)/share vs $(0.07) prior year.
- Cash and investments $6.6M as of March 31, 2026, down from $8.6M at Dec 31, 2025.
- Received initial purchase orders for recombinant bovine transferrin from cultivated meat customers.
- Proliant Health launched AlbuFree™ DX, with Dyadic entitled to profit share; expanded Fermbox Bio collaboration.
- Signed OEM distribution agreement with IBT Bioservices; advanced Gates Foundation RSV/malaria and CEPI/FBS H5 programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226022727/0001493152-26-022727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226022727/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer